Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer

Abstract Objective We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real‐world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clin...

Full description

Saved in:
Bibliographic Details
Main Authors: Hikari Miura, Hayato Yamamoto, Yoshiharu Okuyama, Noritaka Ishi, Ryuma Tanaka, Takuya Oishi, Fumiya Yoneyama, Tomoko Hamaya, Kyo Togashi, Naoki Fujita, Teppei Okamoto, Chikara Ohyama, Shingo Hatakeyama
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Cancer Medicine
Subjects:
ARSI
cost
NDB
prostate cancer
use
Online Access:https://doi.org/10.1002/cam4.70226
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items